Italian Trade Agency at Arab Health supports 160 companies

By HEOR Staff Writer

February 1, 2023

Introduction:

The Italian Trade Agency (ITA) is a government entity promoting Italian products and services. It has thrown its weight behind 160 Italian companies participating in Arab Health 2023.

Arab Health 2023: A Global Healthcare Stage

Arab Health, an annual event that congregates healthcare professionals and companies globally. It is a platform to exhibit the latest products, services, and technological advancements in the healthcare industry. This year’s event, held in Dubai from 30th January to 2nd February, presents a spectrum of healthcare offerings, including innovations like artificial intelligence.

Italian Trade Agency at Arab Health

Located across four different halls, the Italian Pavilion provides a snapshot of Italy’s manufacturing capabilities in the healthcare sector. The pharmaceutical sector, boasting 285 companies employing 67,000 people, stands out for having the most innovative companies. The Italian pharmaceutical industry demonstrates particular prowess in biotech drugs and vaccines. Therefore, establishing Italy as a global hub for research and development (R&D) and production.

Italy’s Vision for the UAE and Sustainability Goals

Lorenzo Fanara, Italy’s Ambassador to the United Arab Emirates (UAE), and Amedeo Scarpa, Italian Trade Commissioner to the UAE, expressed Italy’s vision to strengthen business ties with the UAE, foster long-term investments, and develop industrial partnerships. Under the banner ‘Sustainability is Sustainab-ITALY’, Arab Health 2023 will focus on circular economy and sustainability, reflecting Italy’s pharmaceutical industry’s achievement in reducing energy consumption by 44% over a decade.

Conclusion:

Italian Trade Agency at Arab Health’s support for Italian healthcare companies reflects its commitment to promoting Italy’s robust healthcare sector and its vision for sustainable growth.

Reference url

Recent Posts

Infarmed Regulatory Activity: January 2026 Highlights and Impacts on Market Access

By João L. Carapinha

February 26, 2026

Infarmed regulatory activity in January 2026 showcased robust performance by Portugal's National Authority for Medicines and Health Products, spanning marketing authorizations, clinical trials, public reimbursement, inspections, pharmacovigilance, and enforcement. The agency processed 45 renewals...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per month across key doses, effective January 1, 2027....
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement

By HEOR Staff Writer

February 25, 2026

NICE Backs Ruxolitinib Cream Vitiligo Treatment Ruxolitinib cream vitiligo therapy has received a major endorsement from the National Institute for Health and Care Excellence (NICE), which recommends it for non-segmental vitiligo with...